Decision: Favourable
Study Title:
A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy
NREC Code:
21-NREC-CT-049
Decision:
Favourable
Meeting Date:
11/08/2021
Study Type:
CT application
Principal Investigator:
Prof Ray McDermott
PI Institution:
St Vincent's University Hospital
Sponsor:
Mirati Therapeutics, Inc.